Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, human immunodeficiency virus, herpes simplex virus, and varicella-zoster virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances with AstraZeneca PLC; Merck & Co., Inc.; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Carisma Therapeutics, Inc.; Metagenomi, Inc.; the Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration and license agreement with Chiesi Farmaceutici S.P.A. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

Moderna, Inc.

Biotech 365 provides business support services for biotech companies, focusing on fundraising, licensing, and connecting companies with healthcare investors through their global network.

Biotech 365

Clover Biopharmaceuticals, Ltd., a biotechnology company, engages in the research, development, and commercialization of novel vaccines and biologic therapeutic candidates for infectious diseases, and cancer and autoimmune diseases. It is developing SCB-2019 (CpG 1018/Alum), a COVID-19 vaccine candidate that is in Phase II/III clinical trial; SCB-313, a trimeric fusion protein for the treatment of malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis to address the global unmet medical need of intracavitary malignancies; SCB-808 that is in pivotal Phase III clinical trial for the treatment of rheumatic diseases; SCB-420, an aflibercept biosimilar that is in pre-clinical development for ophthalmologic diseases, such as wet age-related macular degeneration; and SCB-219, a novel TPOR agonist that is in pre-clinical development for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. The company has a collaboration and supply arrangement with Dynavax to supply its CpG 1018 adjuvant for pre-clinical studies. Clover Biopharmaceuticals, Ltd. was founded in 2007 and is headquartered in Shanghai, China.

Clover Biopharmaceuticals, Ltd.

DVLP is building a new infrastructure for drug development by digitizing drug assets, financing, and development workflows to accelerate the process of turning molecules into medicines.

DVLP

Moderna Therapeutics - Messenger RNA Therapeutics

At Moderna, we believe messenger RNA, or mRNA, is the “software of life.”

Every cell in the body uses mRNA to provide real-time instructions to make the proteins necessary to drive all aspects of biology, including in human health and disease.

Given its essential role, we believe mRNA could be used to create a new category of medicines with significant potential to improve the lives of patients.

We are pioneering a new class of medicines made of messenger RNA, or mRNA. The potential implications of using mRNA as a drug are significant and far-reaching and could meaningfully improve how medicines are discovered, developed and manufactured. 

To learn more, visit www.modernatx.com.

This Moderna page is not the appropriate place to report adverse events (side-effects) for any products. If you are or someone you know is experiencing a side effect, please reach out to your healthcare professional. Moderna is continuously monitoring the safety of its products.  We encourage you to report any side effects directly to us at 1‑866‑MODERNA (1‑866‑663‑3762).

Moderna

August is National Immunization Awareness Month! What is #immunization? What is the difference between immunization and #vaccination? Watch the video to learn more 👇🏽

#NIAM #VaccinesWork

Today, we're reporting financial results and providing business updates for the second quarter of 2023. 

Read more: https://lnkd.in/eQX8mPrC

Each person’s #cancer is different, which is why it can be difficult to treat. Hear more from Cleo Constantine Abram about how we’re researching an individualized treatment approach specific to each person's #tumor, with the goal of training their immune system to fight back.

Happy #RNAday! Today, we celebrate the RNA, one of the most versatile biomolecules we have seen come to life. Because of RNA, we have mRNA - and one strand of #mRNA could change how we stand up to multiple diseases – from the widespread to the extremely rare! 🧬🔬

As we continue to build our company, we are committed to accelerating the next generation of leaders - and our co-op program is a powerful example of how we are building the future of Moderna.
 
This spring, we welcomed one of our largest and most diverse cohorts ever – 100 students from 43 schools, with 69% women and 75% from underrepresented groups.
 
Meet and hear from a few of our spring co-ops as they reflect on their experience, in this latest blog from Tracey Franklin, our Chief Human Resources Officer: https://lnkd.in/eYgAc64Q

#CampusRecruiting #CoOp #TeamModerna

#mRNA can potentially change how we fight and prevent diseases. Hear more from Cleo Constantine Abram about the years of work #scientists have done to help us understand what mRNA is and how it can help teach the body to fight back against #diseases. ⬇

Moderna and Merck announced today the initiation of the pivotal Phase 3 randomized V940-001 clinical trial evaluating mRNA-4257 (V940), an investigational individualized neoantigen therapy, in combination with KEYTRUDA, Merck’s anti-PD-1 therapy, as an adjuvant treatment in patients with resected high-risk (Stage IIB-IV) #melanoma.
 
Global recruitment in V940-001 has begun, and the first patients are now enrolling in Australia.
 
Read more: https://lnkd.in/eZTgaFJW

We are proud to be recognized by The Boston Business Journal as one of the most charitable companies in Massachusetts in 2023!

We are honored to receive this recognition and, more importantly, to be able to support local #nonprofit organizations that do incredible work in our communities. Caring deeply about and giving back to the communities where we live and work is an integral part of who we are and what we do.

#ModernaGivesBack #BBJCCA

https://lnkd.in/g4wzCt9A

This week we conducted an onboarding session for our largest cohort of co-ops to date - 122 students!

During onboarding, our latest cohort had the opportunity to put the Moderna #mindsets into practice, learn about employee resource groups and hear from company leaders.

Our co-ops, who represent 26 unique schools, are contributing to impactful projects across all functions at Moderna through mid-December. Join us in welcoming them!

#CampusRecruiting #CoOp #TeamModerna

We're excited to share that Rose Loughlin, our Senior Vice President of Research and Early Development, has been recognized by Endpoints News as one of 20 extraordinary women worldwide who are reshaping #biopharma.
 
Rose joined Moderna nearly 8 years ago, and is responsible for platform research, therapeutics discovery (#cancer, rare diseases, #autoimmune), and non-clinical development.
 
Congratulations, Rose! We look forward to seeing how you and your teams can continue to deliver the greatest possible impact to people through #mRNA #medicines.
 
https://lnkd.in/eMbb4TAj

Metric
Company Name	Moderna, Inc.	Biotech 365	Clover Biopharmaceuticals, Ltd.	DVLP
Symbol	MRNA		2.20K
MSH ID	COM:MODERNATX	COM:BIOTECH-365	COM:CLOVERBIOPHARMA	COM:DVLPMEDICINES
Market	STOCKS	PRIVATE	STOCKS	PRIVATE
Sector	Healthcare	Financial Services & Finance	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology Business Services	Biotechnology	Pharmaceuticals
Country	US	FR	CN	US
Stage			Post-IPO Equity
Employee Count	5.60K		387
Website	modernatx.com	biotech-365.com	cloverbiopharma.com	dvlpmedicines.com
LinkedIn			cloverbiopharmaceuticals	dvlpmedicines
Founders

Metric
Market Cap	45.01B		53.38M
Enterprise Value
Monthly Web Traffic		68	3.49K	133
Web Traffic Growth		-0.57	0.41	-0.55
Valuation
Raised Capital			36.90M

Metric
Revenue	6.75B	5.40M
Revenue (LTM)
Revenue (NTM)
Gross Profit	2.06B	-230.14M
EBITDA	-3.21B	-354.93M
Operating Income	-4.24B	-358.92M
Net Income	-4.71B	-19.06M
EPS	-12.34	-0.02
Diluted EPS	-12.34	-0.02
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.32	-15.46
Operating Profit Margin	-0.62	-34.22
EBITDA Margin	-0.48	-65.74
Net Profit Margin	-0.69	-3.53
Return on Equity	-0.30	2.08
Return on Assets	-0.26	-0.07
Return on Capital Employed	-0.28	14.86

COM:MODERNATX

Moderna Inc.

Last Close

38.25

22/11 21:00

Market Cap

45.01B

Beta: -

Volume Today

13.33M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-10.50	-0.17
P/B Ratio	2.71	-0.64
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	12.39	1.95K
EV Multiple	-5.48	-0.25

Metric
Days Sales Outstanding	74.67
Days Payables Outstanding	31.73
Days Inventory Outstanding	42.12	534.63
Operating Cycle	73.31	1.07K
Cash Conversion Cycle	43.23	1.03K
Asset Turnover	0.37	0.02

Metric
Operating Cash Flow	-3.12B
Free Cash Flow	-3.83B
Cash Flow to Debt	-2.28	-1.29
Operating Cash Flow/Sales	-0.46	-10.96
Free Cash Flow Yield	-0.07	-3.59

Metric
Cash & Equivalents	2.91B	101.22M
Accounts Receivable	493M
Inventory	202M	95.87M
Goodwill	52M
Debt to Capitalization	0.10	0.94
Debt to Assets	0.07	0.08
Current Ratio	2.46	1.55
Quick Ratio	3.92	0.55

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.03
R&D to Revenue	0.51
SG&A to Revenue